GRI BioGRI
GRI
About: GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Employees: 4
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
273% more capital invested
Capital invested by funds: $49.7K [Q3] → $185K (+$136K) [Q4]
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
14% more funds holding
Funds holding: 7 [Q3] → 8 (+1) [Q4]
2.2% less ownership
Funds ownership: 4.7% [Q3] → 2.51% (-2.2%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for GRI.
Financial journalist opinion
Based on 7 articles about GRI published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
GRI Bio Announces Closing of $5.0 Million Public Offering
LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of common stock, short-term Series E-2 warrants to purchase up to 1,388,888 shares of common stock and short-term Series E-3 warrants to purchase up to 1,388,888 shares of common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $3.60 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants have an exercise price of $3.20 per share and are exercisable immediately upon issuance. The Series E-1 warrants expire on the five-year anniversary of the initial issuance date. The short-term Series E-2 warrants expire on the eighteen-month anniversary of the initial issuance date. The short-term Series E-3 warrants expire on the nine-month anniversary of the initial issuance date.
Neutral
Zacks Investment Research
1 week ago
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
GRI stock plunges on the pricing of its public offering, paring the gains witnessed following positive IPF study results.
Neutral
GlobeNewsWire
1 week ago
GRI Bio Announces Pricing of $5.0 Million Public Offering
LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of common stock, short-term Series E-2 warrants to purchase up to 1,388,888 shares of common stock and short-term Series E-3 warrants to purchase up to 1,388,888 shares of common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $3.60 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants will have an exercise price of $3.20 per share and will be exercisable immediately upon issuance. The Series E-1 warrants will expire on the five-year anniversary of the initial issuance date. The short-term Series E-2 warrants will expire on the eighteen-month anniversary of the initial issuance date. The short-term Series E-3 warrants will expire on the nine-month anniversary of the initial issuance date. The closing of the offering is expected to occur on or about April 2, 2025, subject to the satisfaction of customary closing conditions.
Positive
Benzinga
1 week ago
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?
GRI Bio, Inc. GRI stock is trading on Tuesday with a strong session volume of 6.9 million compared to an average volume of 17.35K, as per data from Benzinga Pro.
Neutral
GlobeNewsWire
1 week ago
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases
Neutral
GlobeNewsWire
3 weeks ago
GRI Bio Participates in a Virtual Investor CEO Connect Segment
Access the CEO Connect segment here
Neutral
GlobeNewsWire
3 weeks ago
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively Cash runway expected to fund operations into Q2 2025, including interim data readout from GRI-0621 LA JOLLA, CA, March 17, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, has reported its financial results for the fiscal year ended December 31, 2024 and today provided a corporate update. “Over the last year, we made significant progress on the development of our lead program GRI-0621 for the treatment of IPF.
Neutral
GlobeNewsWire
1 month ago
GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule
LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it received notice on March 10, 2025 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2), also known as the “minimum bid price rule.”
Neutral
GlobeNewsWire
1 month ago
GRI Bio Announces Reverse Stock Split
GRI's common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025 LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-17 reverse stock split (the “Reverse Split”) of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on February 11, 2025.
Neutral
GlobeNewsWire
1 month ago
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here
Charts implemented using Lightweight Charts™